Status:
COMPLETED
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a gene...
Eligibility Criteria
Inclusion
- Clinical DSM-IV diagnosis of schizophrenia
- Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required
Exclusion
- Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes
- Prisoners or subjects compulsory detained
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00237939
Start Date
September 1 2002
End Date
November 1 2006
Last Update
November 8 2013
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Antwerp, Belgium
2
Local Institution
Brussels, Belgium
3
Local Institution
Diest, Belgium
4
Local Institution
Kortenberg, Belgium